Ars Pharmaceuticals Inc Revenue Growth Rates (SPRY), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Ars Pharmaceuticals Inc   (NASDAQ: SPRY)
 

SPRY's Revenue Growth by Quarter and Year

Ars Pharmaceuticals Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

SPRY Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June 33.66
1st Quarter March 22.68
FY 56.34





SPRY Revenue second quarter 2026 Y/Y Growth Comment
Ars Pharmaceuticals Inc achieved in the second quarter 2026, above Company average Revenue surge of 114.11% year on year, to $ 33.66 millions.

Looking into second quarter 2026 results within Major Pharmaceutical Preparations industry 70 other companies have achieved higher Revenue growth. While Ars Pharmaceuticals Inc ' s Revenue doubling of 114.11% ranks overall at the positon no. 1057 in the second quarter 2026.


SPRY Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - -67.56 % - -
3rd Quarter September - 1470.05 % - -
2nd Quarter June 114.11 % 3044 % 4900 % -97.83 %
1st Quarter March 184.57 % - - -96.97 %
FY   - -5.46 % 297066.67 % -

Financial Statements
Ars Pharmaceuticals Inc 's second quarter 2026 Revenue $ 33.66 millions SPRY's Income Statement
Ars Pharmaceuticals Inc 's second quarter 2025 Revenue $ 15.72 millions Quarterly SPRY's Income Statement


SPRY Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - -13.57 % 4082.61 % -
3rd Quarter September - 106.74 % 314 % -
2nd Quarter June 48.4 % 97.24 % - -50 %
1st Quarter March -19.26 % -90.79 % - -
FY (Year on Year)   - -5.46 % 297066.67 % -


Back to SPRY Growth rate Comparisons >> Back to SPRY Growth rate Comparisons >>


Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #71
Healthcare Sector #203
Overall #1057

Revenue Y/Y Growth Statistics
High Average Low
4.08 % 3 % 1.92 %
(Jun 30 2026)  
Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #71
Healthcare Sector #203
Overall #1057
Revenue Y/Y Growth Statistics
High Average Low
4.08 % 3 % 1.92 %
(Jun 30 2026)  

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Ars Pharmaceuticals Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
4086.7 % 322.29 % -100 %
(Dec 31 2024)  


SPRY's II. Quarter Q/Q Revenue Comment
Ars Pharmaceuticals Inc achieved in the II. Quarter 2026 below company average Revenue jump of 48.4% quarter on quarter, to $ 33.66 millions.

Within Major Pharmaceutical Preparations industry 34 other companies have achieved higher Revenue quarter on quarter growth. While Ars Pharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 245.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #35
Healthcare Sector #66
Overall #245
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #35
Healthcare Sector #66
Overall #245
Revenue Q/Q Growth Statistics
High Average Low
4086.7 % 322.29 % -100 %
(Dec 31 2024)  


SPRY's II. Quarter Q/Q Revenue Comment
Ars Pharmaceuticals Inc achieved in the II. Quarter 2026 below company average Revenue jump of 48.4% quarter on quarter, to $ 33.66 millions.

Within Major Pharmaceutical Preparations industry 34 other companies have achieved higher Revenue quarter on quarter growth. While Ars Pharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 245.


Ars Pharmaceuticals Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 116.93 $ 98.99 $ 84.28 $ 142.77 $ 112.34
Y / Y Revenue Growth (TTM) 4.08 % 1.92 % - - -
Year on Year Revenue Growth Overall Ranking # 2391 # 1958 # 0 # 0 # 0
Seqeuential Revenue Change (TTM) 18.12 % 17.45 % -40.97 % 27.09 % 15.67 %
Seq. Revenue Growth (TTM) Overall Ranking # 1057 # 826 # 709 # 331 # 655


Cumulative Revenue growth Comment
With 4.08% annual Revenue growth, Ars Pharmaceuticals Inc would report a record annual Revenue improvement if the fiscal year would end on Jun 30 2026.

In the Healthcare sector 347 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1958 to 2391.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 71
Healthcare Sector # 348
Overall # 2391

Revenue TTM Y/Y Growth Statistics
High Average Low
4.08 %
 3 %
1.92 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 71
Sector # 203
S&P 500 # 1057
Cumulative Revenue growth Comment
With 4.08% annual Revenue growth, Ars Pharmaceuticals Inc would report a record annual Revenue improvement if the fiscal year would end on Jun 30 2026.

In the Healthcare sector 347 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1958 to 2391.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 71
Healthcare Sector # 348
Overall # 2391

Revenue TTM Y/Y Growth Statistics
High Average Low
4.08 %
3 %
1.92 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 71
Sector # 203
S&P 500 # 1057




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
SPRY's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue improvement for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Sintx Technologies Inc 199.34%$ 199.338 millions
Arrowhead Pharmaceuticals Inc 171.02%$ 171.016 millions
Cue Biopharma Inc 166.66%$ 166.655 millions
Qt Imaging Holdings Inc exact Name Of Registrant As Specified In Its Charter _______________________162.99%$ 162.992 millions
Cormedix Inc 156.52%$ 156.515 millions
Ataibeckley Inc 137.00%$ 136.996 millions
Pavmed Inc 135.71%$ 135.714 millions
Xilio Therapeutics Inc 131.22%$ 131.222 millions
Tenon Medical Inc 126.77%$ 126.773 millions
Sonida Senior Living Inc 122.02%$ 122.024 millions
Bridgebio Pharma Inc 120.39%$ 120.392 millions
Autolus Therapeutics Plc118.37%$ 118.367 millions
Neuraxis Inc 115.72%$ 115.717 millions
Renovorx Inc 115.40%$ 115.403 millions
Ars Pharmaceuticals Inc 114.15%$ 114.150 millions
Foghorn Therapeutics Inc 112.68%$ 112.677 millions
60 Degrees Pharmaceuticals Inc 106.04%$ 106.044 millions
Mobia Medical Inc 102.35%$ 102.352 millions
Ptc Therapeutics inc 101.55%$ 101.548 millions
Eton Pharmaceuticals Inc 98.63%$ 98.631 millions
Immunitybio inc 93.91%$ 93.907 millions
Syndax Pharmaceuticals Inc 91.76%$ 91.759 millions
Phathom Pharmaceuticals Inc 88.02%$ 88.021 millions
Fennec Pharmaceuticals Inc 85.18%$ 85.184 millions
Alamar Biosciences Inc 82.08%$ 82.075 millions
Seastar Medical Holding Corp81.95%$ 81.953 millions
Sera Prognostics Inc 76.47%$ 76.471 millions
Innovative Eyewear Inc 74.46%$ 74.459 millions
Madrigal Pharmaceuticals Inc 71.17%$ 71.169 millions
Tg Therapeutics Inc 70.27%$ 70.272 millions


About Ars Pharmaceuticals Inc Revenue Growth Rates (SPRY), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Ars Pharmaceuticals Inc (CIK 1671858).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001193125-26-349140
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Ars Pharmaceuticals Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.